Diego Kauffmann‐Guerrero

Author

Ludwig-Maximilians-Universität München ORCID

Also Known As

D Kauffmann-Guerrero, D. Kauffmann-Guerrero, DIEGO KAUFFMANN-GUERRERO, Diego Erich Kauffmann-Guerrero, Diego Kauffmann-Guerrero, Diego Kauffmann‐Guerrero, Jürgen Behr, Kauffmann-Guerrero D

139

Publications

929

Citations

H-Index

Concepts

All Affiliations

Ludwig-Maximilians-Universität München German Center for Lung Research Heidelberg University LungenClinic Grosshansdorf University Hospital Heidelberg

About

Diego Kauffmann‐Guerrero is an author at Ludwig-Maximilians-Universität München specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	218
2	Immunology	4	4	178
3	Pathology	3	3	49
4	Orthopaedics	2	2	98
5	Health Sciences	1	1	16

Diego Kauffmann‐Guerrero

Publications

653

Citations

H-Index

Page 1

	Year	Citations
Treatment outcome of atypical EGFR mutations in the German National Network Genomic Medicine Lung Cancer (nNGM) Melanie Janning, Juliane Süptitz, Corinna Albers, Annals of Oncology	2022	87
Characteristics and treatment of new-onset arthritis after checkpoint inhibitor therapy Jan Leipe, Lisa Christ, Andreas Arnoldi, RMD Open Disease BurdenImmunologyCheckpoint Inhibitor TherapyImmunotherapyPsoriatic Arthritis	2018	85
Systemic inflammation and pro-inflammatory cytokine profile predict response to checkpoint inhibitor treatment in NSCLC: a prospective study Diego Kauffmann‐Guerrero, Kathrin Kahnert, Rosemarie Kiefl, Scientific Reports	2021	65
Efficacy of Immune Checkpoint Inhibitors Alone or in Combination With Chemotherapy in NSCLC Harboring ERBB2 Mutations Felix Carl Saalfeld, Carina Wenzel, Petros Christopoulos, Journal of Thoracic Oncology MedicineImmunologyImmune Checkpoint InhibitorCancer TreatmentImmunotherapy	2021	58
Lorlatinib in pretreated ALK- or ROS1-positive lung cancer and impact of TP53 co-mutations: results from the German early access program Nikolaj Frost, Petros Christopoulos, Diego Kauffmann‐Guerrero, Therapeutic Advances in Medical Oncology	2021	47
Outcome of First-Line Treatment With Pembrolizumab According to KRAS/TP53 Mutational Status for Nonsquamous Programmed Death-Ligand 1–High (≥50%) NSCLC in the German National Network Genomic Medicine Lung Cancer Philip Bischoff, Martin Reck, Tobias R. Overbeck, Journal of Thoracic Oncology	2023	42
Response to Checkpoint Inhibition in Non-Small Cell Lung Cancer with Molecular Driver Alterations Diego Kauffmann‐Guerrero, Amanda Tufman, Kathrin Kahnert, Oncology Research and Treatment	2020	36
Standardized airway wall thickness Pi10 from routine CT scans of COPD patients as imaging biomarker for disease severity, lung function decline, and mortality Kathrin Kahnert, Rudolf A. Jörres, Hans‐Ulrich Kauczor, Therapeutic Advances in Respiratory Disease	2023	29
NSCLC Patients Harbouring Rare or Complex EGFR Mutations Are More Often Smokers and Might Not Benefit from First-Line Tyrosine Kinase Inhibitor Therapy Diego Kauffmann‐Guerrero, Rudolf M. Huber, Simone Reu, Respiration	2017	23
The impact of TP53 co-mutations and immunologic microenvironment on outcome of lung cancer with EGFR exon 20 insertions Petros Christopoulos, Klaus Kluck, Martina Kirchner, European Journal of Cancer Immunologic MicroenvironmentMedicineImmunologyPathologyCancer Genomics	2022	22

Page 1